Oncotarget Became a Great Resource for Oncologists

Since Oncotarget first started, publications like Research Gate have been looking at how they are changing the industry. They know what they are doing and they also know they are able to make a difference for all the people who are a part of the community. Since Oncotarget knows what they are doing and since they are so focused on how to change the oncology world, they are always prepared to help people through the issues they are facing. They know what it will take to bring attention to the things they can do to make the industry better. For the company, this means they have to try their best to make things easier and to make things better for themselves. They know what they want to be able to do and they know they are going to try and help people through different situations. Follow Oncotarget on Twitter.

Being a part of a peer review publication like Oncotarget has allowed those who are working with the company the chance to try different things with their patients. They have found out about cancer treatment options and they use them so they won’t have to worry about how they are going to get the treatment they need. All of this goes back to how they can be a positive influence for patients. Oncotarget knows what it takes and isn’t afraid to give people the options they need to make cancer treatment better. They want to help all their patients feel they are getting the best treatment possible.

Listen: https://player.fm/series/oncotarget

Even recently, Oncotarget was learning how to help even more people. They found out about the treatment that could be used for thyroid cancer. This was a type of treatment they had never used before and it was something they were sure would work to their advantage. For everyone who was in the industry, Oncotarget was prepared to make things easier for their patients. They wanted them to realize there were other things that were going on and there were options their patients would have a chance to experience so they wouldn’t have to worry about how they were fixing things or making them better. Learn more at researchgate.net

The Accomplishments of Dr. Clay Seigall at Seattle Genetics

Clay Seigall is a renowned science expert in the pharmaceutical sector. He is the founder of a leading biotechnology firm that is known as Seattle Genetics. The company has been operational since 1998, and Seigall acts as the chairman of its board. He has been a great leader of the business and has assisted it in making significant accomplishments. The company has developed various cancer therapies that have gained the approval of the FDA.


Dr. Siegall has strived to ensure that the firm obtains sufficient funds to conduct its research undertakings. He has led it in raising over $670 million through private and public funding efforts. Before the establishment of Seattle Genetics, Clay was an employee of Bristol-Myers Squib Pharmaceutical Research Institute as from 1991 to 1997. He also worked for a government-owned body that is called the National Cancer Institute. Siegall was appointed to serve on the boards of organizations such as the Biomedical Association and Washington Biotechnology. He sits on the board of Alder BioPharmaceuticals, which is privately held biotechnology enterprise.


Clay has conducted a lot of research about cancer and has written more than 70 publications. He also has about 15 patents for various products that he has established. Siegall completed his undergraduate studies in Zoology from the University of Maryland and was awarded a Ph.D. at the George Washington University. Seattle Genetics has been successful in the development of antibody-based therapies that are used in curing cancer. It has created effective antibody-drug conjugates (ADCs), and the technology has been utilized in the formation of more than 21 drugs. The company has commercialized its medicines in the USA and other parts of the globe.


Seattle Genetics has collaborated with corporations such as Takeda Pharmaceutical Company to sell drugs in different regions of the world. It has also joined efforts with Genentech in developing SGN-40. The partnership of the two firms is valued at about $860 million. The world currently needs advanced cancer treatments that cause less harm to the human body. ADCs have been working efficiently, and various companies use the technology in developing drugs.